Evidence map›Paper›PMID 27070110›Full record

ArticleInvestigative ophthalmology & visual science2016

Elevated CD1c+ Myeloid Dendritic Cell Proportions Associate With Clinical Activity and Predict Disease Reactivation in Noninfectious Uveitis.

Ping Chen, Cristhian A Urzua, Jared E Knickelbein, Jane S Kim, Zhiyu Li, Susan Hannes, David Kuo, Benjamin Chaigne-Delalande, Karen Armbrust, William Tucker and 4 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Investigative ophthalmology & visual science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Ping ChenLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Cristhian A UrzuaLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States 2Department of Ophthalmology, Universidad de Chile, Santiago, Chile.
Jared E KnickelbeinLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Jane S KimLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States 3School of Medicine, University of California San Diego, La Jolla, California, United States.
Zhiyu LiLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Susan HannesLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
David KuoLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States 3School of Medicine, University of California San Diego, La Jolla, California, United States.
Benjamin Chaigne-DelalandeLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Karen ArmbrustLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
William TuckerLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Baoying LiuLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Elvira AgrónDivision of Epidemiology and Clinical Application, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
H Nida SenLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Robert B NussenblattLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
National Eye Institute · USNational Institutes of Health · USUniversity of California, San Diego · US

Funding

Cellular and molecular mechanisms in Age Related Macular Degeneration & UveitisZIAEY000464 · NEI · NATIONAL EYE INSTITUTE · PI CHAIGNE-DELALANDE, BENJAMIN · 2009 to 2016
$2.4M
Studies of Ocular inflammation: Clinical researchZIAEY000557 · NEI · NATIONAL EYE INSTITUTE · PI SEN, HATICE · 2017 to 2018
$2.0M
Intramural NIH HHS
6 · The paper itself

Abstract

purposeTo test the association between elevated proportions of CD1c+ myeloid dendritic cells (mDCs) and disease activation/reactivation in noninfectious uveitis.

methodsNoninfectious uveitis patients (n = 89) and healthy controls (n = 111) were recruited. The proportion of CD1c+ mDCs in the total dendritic cell (DC) population of peripheral blood was measured by flow cytometry (CD1c+ mDCs gated on Lineage 1+HLADR+ DCs). Disease activity was assessed per Standardization of Uveitis Nomenclature criteria. Uveitis reactivation was ascribed to clinically quiescent patients who developed reactivation of intraocular inflammation within 6 months.

resultsThe proportions of CD1c+ mDCs were increased in noninfectious uveitis patients, especially in active disease, compared to healthy controls. This CD1c+ mDC elevation was not associated with underlying systemic diseases, anatomic locations of uveitis, medications, or demographic factors. Longitudinal data showed that the dynamics of CD1c+ mDC levels were correlated with disease activity. The average proportion of CD1c+ mDCs in active uveitis patients was 60% so we set this as the cutoff between high and low CD1c+ mDC levels. Although 74% of quiescent patients had low proportions of CD1c+ mDCs, 26% still had high proportions. Quiescent patients with high CD1c+ mDC proportions showed increased risk of disease reactivation, compared to quiescent patients with low CD1c+ mDC proportions.

conclusionsIncreased proportions of CD1c+ mDCs were associated with clinical activity, and quiescent patients with elevated CD1c+ mDCs were more likely to undergo reactivation. This suggests that CD1c+ mDC proportion may be a potential biomarker for assessing clinical activation and reactivation in noninfectious uveitis.

Indexed as

Immunity, CellularAdolescentAdultAgedAged, 80 and overAntigens, CD1BiomarkersCell CountChildDendritic CellsDisease ProgressionFemaleFlow CytometryFollow-Up StudiesGlycoproteinsHumansAntigens, CD1BiomarkersCD1C protein, humanGlycoproteins

Identifiers

PMID27070110
PMCPMC4849533
OpenAlexW2341476536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.